LRRK2 Parkinson’s Disease: Increasing Awareness and Genetic Testing Program

This study aims to support the development of a targeted precision medicine intended to treat patients with a genetic form of Parkinson’s disease by providing participants with free genetic testing. Up to 15% of cases of Parkinson’s disease have an underlying genetic cause, yet many patients have never had genetic testing as there is often no family history of the disease.

In instances of Parkinson’s where the disease is caused by genetics, one of the most common reasons for this is a mutation in a gene called LRRK2 (Pronounced “Lark-two”). The genetic mutation can occur in anyone with Parkinson’s and comprises up to 30% of all Parkinson’s cases in people of Ashkenazi Jewish or North African Arabic ancestry. Additionally, patients with young onset Parkinson’s or a family history of the disease are more likely to have this mutation. ESCAPE Bio (ESCAPE) is investigating this mutation in order to help develop a new treatment specifically for people with Parkinson’s who have a form of this LRRK2 genetic mutation which is called G2019S.

This research study will be very important in supporting the future development of a new oral medicine treatment for one of the most common genetic forms of Parkinson’s, aimed at slowing the progression of the disease.

https://bit.ly/3jdAEim

Genetic Parkinson's disease This study aims to support the development of a precision medicine intended to treat patients with genetic forms of Parkinson's disease.